Details for Patent: 12,667,575

Which drugs does patent 12,667,575 protect, and when does it expire?

Patent 12,667,575 protects REZDIFFRA and is included in one NDA.

This patent has seven patent family members in five countries.

Drugs Protected by US Patent 12,667,575

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No						TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) WHO ARE USING A MODERATE CYP2C8 INHIBITOR
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No						TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) WHO ARE USING A MODERATE CYP2C8 INHIBITOR

International Family Members for US Patent 12,667,575

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2025217722
China	122580099
European Patent Office	4658275
European Patent Office	4803100
Israel	328308